Hepion Pharmaceuticals, Inc. (HEPA): Nasdaq/NYSE listing notice — Hepion Pharma receives Nasdaq delisting notice for failure to hold annual meeting; 45 days to submit compliance plan

Hepion Pharmaceuticals, Inc.

Notice dated January 14, 2025 from Nasdaq for failing to hold annual shareholders' meeting within 12 months of fiscal year end.
Company has 45 days to submit a plan to regain compliance; intends to do so.
If plan accepted, Nasdaq may grant extension to June 30, 2025; if not, company can appeal.
Common stock (HEPA) continues trading on Nasdaq Capital Market during the process.
No assurance that listing will be maintained.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Hepion Pharmaceuticals, Inc. received a nasdaq deficiency notice notice regarding shareholders.

Exchange: nasdaq
Notice: deficiency notice
Deficiency: shareholders

Exact text from the filing

January 14, 2025, Hepion Pharmaceuticals, Inc., a Delaware corporation (the “ Company ”), received written notice (the “ Notice ”) from the Nasdaq Stock Market, LLC (“ Nasdaq ”) indicating that since the Company had not

View on SEC.gov

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Hepion Pharmaceuticals, Inc. received a nasdaq deficiency notice notice regarding shareholders.

Exchange: nasdaq
Notice: deficiency notice
Deficiency: shareholders

Exact text from the filing

January 14, 2025, Hepion Pharmaceuticals, Inc., a Delaware corporation (the “ Company ”), received written notice (the “ Notice ”) from the Nasdaq Stock Market, LLC (“ Nasdaq ”) indicating that since the Company had not held an annual meeting of shareholders within twelve months of the Company’s fiscal year end (the “Listing Rule”), the Company no longer complies with the Listing Rule for continued listing. The Notice has no effect at this time on the Common Stock, which continues to trade on the Nasdaq Capital Market under the symbol “HEPA.” Under the Listing Rule, the Company has 45 days to

View on SEC.gov

Browse all listing & compliance notices →

Hepion Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-25-002377

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.